首页> 美国卫生研究院文献>Case Reports in Oncology >A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab
【2h】

A Report of Disseminated Carcinomatosis of the Bone Marrow Originating from Transverse Colon Cancer Successfully Treated with Chemotherapy Using XELOX plus Bevacizumab

机译:XELOX +贝伐单抗成功化学疗法治疗源自横结肠癌的骨髓弥漫性癌变的报道

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 61-year-old male, who had been admitted to another hospital due to disseminated intravascular coagulation (DIC), was referred to our hospital. Total colonoscopy, abdominal dynamic CT and positron-emission tomography revealed bone metastasis and multiple lymphocytic metastases from transverse colon cancer in addition to disseminated carcinomatosis of the bone marrow (DCBM). We immediately performed chemotherapy with XELOX + bevacizumab and denosumab against DCBM from transverse colon cancer in order to avoid radical surgery. In addition, we initiated the administration of recombinant human soluble thrombomodulin for 1 week to treat DIC. The patient was able to tolerate and receive 4 cycles of chemotherapy without any severe side effects. After receiving the 4 cycles of treatment, he recovered from DIC, and the bone and multiple lymphocytic metastases disappeared.
机译:一名因弥散性血管内凝血(DIC)而入院的61岁男性被转诊至我院。全结肠镜检查,腹部动态CT和正电子发射断层扫描显示,除了弥漫性骨髓癌(DCBM)之外,横向结肠癌还发生了骨转移和多发性淋巴细胞转移。为了避免进行根治性手术,我们立即用XELOX +贝伐单抗和地诺单抗针对横结肠癌的DCBM进行了化疗。此外,我们开始给予重组人可溶性血栓调节蛋白治疗1周以治疗DIC。该患者能够耐受并接受4个周期的化疗,而没有任何严重的副作用。在接受了4个疗程的治疗后,他从DIC中康复,骨骼和多发性淋巴细胞转移消失了。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号